Zacks Industry Outlook Highlights Natural Gas Services, Solaris Energy and Oil States International
Chicago, IL – May 28, 2025 – Today, Zacks Equity Research discusses Natural Gas Services Group, Inc. NGS, Solaris Energy Infrastructure, Inc. SEI and Oil States International, Inc. OIS.
Industry: Oil & Gas Equipment
Link: https://www.zacks.com/commentary/2477230/3-oil-gas-equipment-stocks-to-sail-through-industry-challenges
Rising oil production that may surpass the yearly demand growth of the commodity will probably drag down prices. This will hurt demand for drilling and production equipment as explorers and producers will be reluctant to produce more of the commodity, creating a challenging outlook for the Zacks Oil and Gas- Mechanical and Equipment industry.
Companies striving to navigate these industry challenges include Natural Gas Services Group, Inc., Solaris Energy Infrastructure, Inc. and Oil States International, Inc.
The Zacks Oil and Gas - Mechanical and Equipment industry comprises companies that provide necessary oilfield equipment — production machinery, pumps, valves and several other drilling appliances like rig components — to exploration and production companies. These help upstream energy players extract crude oil and natural gas from fields, both onshore and offshore.
Hence, the well-being of oilfield equipment businesses is positively correlated to expenditures by upstream companies. These companies receive deals from integrated energy firms and independent as well as national oil and gas companies. Oilfield equipment providers also design, manufacture, engineer and install products used to treat and process crude oil, natural gas and others. Their products comprise gadgets and instruments for gas compression packages and water treatment works.
: The U.S. Energy Information Administration ('EIA') is expecting the West Texas Intermediate Spot Average price for 2025 and 2026 at $61.81 per barrel and $55.24 per barrel, respectively. The prices are significantly lower than the $76.60 per barrel price for 2024.
EIA cited the increasing production volumes of the commodity to overcome yearly crude oil demand growth as the reason for lower oil prices. Thus, a lower pricing environment of the commodity is unlikely to provide incentives for more exploration and production activities, consequently leading to diminished demand for drilling and production equipment of companies in the industry.
Exploration and production companies are becoming more conservative in their capital expenditures for upstream operations. This shift is driven by shareholders who want these companies to prioritize returning capital over increasing spending on production. This trend is likely to diminish demand for drilling and production equipment.
: The composite stocks belonging to the industry have consistently been generating lower dividend yield than the oil energy sector over the past five years. Thus, investors looking for a healthy dividend yield may avoid stocks belonging to the industry.
The Zacks Oil and Gas - Mechanical and Equipment is a 11-stock group within the broader Zacks Oil - Energy sector. The industry currently carries a Zacks Industry Rank #206, which places it in the bottom 16% of more than 250 Zacks industries.
The group's Zacks Industry Rank, which is basically the average of the Zacks Rank of all the member stocks, indicates dull near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Before we present a few stocks that you may want to consider, let's take a look at the industry's recent stock market performance and valuation picture.
The Zacks Oil and Gas - Mechanical and Equipment industry has outperformed the broader Zacks Oil - Energy sector but lagged the Zacks S&P 500 composite over the past year.
The industry has declined 3.9% in the past year compared with the broader sector's fall of 4.6% and the S&P 500's 10.8% increase.
Since oilfield equipment providers are debt-laden, valuing them based on the EV/EBITDA (Enterprise Value/Earnings before Interest Tax Depreciation and Amortization) ratio makes sense. This is because the valuation metric takes into account not just equity but also the level of debt. For capital-intensive companies, EV/EBITDA is a better valuation metric because it is not influenced by changing capital structures and ignores the effect of non-cash expenses.
On the basis of the trailing 12-month enterprise value-to-EBITDA (EV/EBITDA), the industry is currently trading at 5.66X, lower than the S&P 500's 16.39X. However, it is higher than the sector's trailing 12-month EV/EBITDA of 4.59X.
Over the past five years, the industry has traded as high as 43.82X and as low as 1.11X, with a median of 10.37X.
Natural Gas Services: The United States is sending more natural gas overseas as Liquefied Natural Gas (LNG). To do this, gas needs to travel through pipelines to coastal export terminals. This creates higher demand for Natural Gas Services' compression equipment to push the gas through the pipelines. So, as more LNG is exported and more pipelines are built, companies like NGS, sporting a Zacks Rank #1 (Strong Buy), benefit by renting out more of their compression machines. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Solaris Energy: Despite a dip in oil prices, Solaris Energy, carrying a Zacks Rank #3 (Hold), hasn't experienced any major decline in business. It anticipates stable activity through the early part of the second quarter, with its logistics systems, key to supporting drilling and fracking, still in strong demand. In the first quarter, system activity rose more than 25%, and its top-fill systems were nearly fully deployed. While some operators may reduce activity later in the year if oil prices remain soft, SEI's oil and gas logistics business has proven resilient, contributing to more stable and predictable income.
Oil States International: Oil States International, carrying a Zacks Rank 3, is getting a lot of new business from customers outside the United States, especially from companies working in deep ocean areas to extract oil and gas. In fact, it received more orders than it delivered this past quarter, 1.5 times more, which is a great sign. That means more activities and cash flow are lined up for the future.
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Oil States International, Inc. (OIS) : Free Stock Analysis Report
Natural Gas Services Group, Inc. (NGS) : Free Stock Analysis Report
Solaris Energy Infrastructure, Inc. (SEI) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Confused by latest order? How to calculate if your Jackson County assessment is within limits
KANSAS CITY, Mo. — Jackson County assessments are showing up in homeowner's mailboxes. Some people may be surprised at the increase after a May order from the State Tax Commission. Some taxpayers may receive tax refunds in June: When payments could arrive That order capped increases in each assessment period at 15% and set 2022 as a starting point for this year's assessments after 2023 assessments were heavily contested. But determining your maximum 2025 assessment is a little bit more complicated than a single multiplication or division. Legislator Sean Smith and Preston Smith (no relation) have been helping homeowners with appeals since assessments skyrocketed in 2023. This week as they went out again they've been getting questions about what the latest State Tax Commission Order and 15% cap really means. 'People look at it and the first thing they see is, I thought it was only going to be a 15% increase and that was the perception. I've probably answered it online 100 times,' Preston Smith said. 'A lot of people are contacting me thinking they only do the 15 percent once, but you have to do it twice,' Legislator Sean Smith explained. To illustrate how it works with the latest rules using 2022 assessments as the starting point, consider a home with a $100,000 assessed value in 2022. To calculate the maximum assessed value in 2023 multiply $100,000 by 1.15 which is $115,000. But then you have to multiply by 115% again to determine the maximum value a home could be assessed at this year. In this example it would be $132,250. The two 15% increases end up yielding a maximum increase of 32.25% during the two assessment periods. 'I would really urge people to do the math themselves to check it, check and really verify,' Preston Smith said. To do that, however, you have to know your home's 2022 assessed value, which according to those who have received this year's assessments, isn't on this year's notices. You can find that historical information online at the Jackson County Parcel Viewer or Ascend Web. If your increase ends up beyond the allowances under the State order or if you simply don't agree with your value, you still can appeal. Appeals have to be filed by July 14. Download WDAF+ for Roku, Fire TV, Apple TV As for seniors, 40,000 are already enrolled in a new tax credit program freezing tax bills. The county says estimated savings are included on notices, but are subject to change. Both Sean and Preston Smith say they are pressing the Assessor's Office for complete assessment data in 2022, 2023 and 2025 to see how much home values increased, and how many of those increases equated to the maximum allowed if no new construction was done under the State Tax Commission Order without a physical inspection. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
5 hours ago
- Yahoo
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial
On June 4, analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Immix Biopharma, Inc. (NASDAQ:IMMX) with a price target of $7.00. The analyst based the rating on the promising interim results from the NEXICART-2 Phase 1/2 clinical trial of NXC-201, presented at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) in Chicago, Illinois. The trial assessed the efficacy of NXC-201 in patients with relapsed/refractory AL amyloidosis and delivered a 100% response rate, with a considerable portion attaining a complete hematologic response. The analyst reasoned that the absence of hematologic relapse or progression and the rapid mean time to response further highlight NXC-201's potential as a viable treatment. A doctor in a white coat discussing clinical trial results with a patient in an oncology practice. Burns also reasoned that NXC-201 appears to have a favorable safety profile, as no patients experienced severe cytokine release syndrome or neurotoxicity. While he highlighted the need for longer-term follow-up and the small sample size, the analyst stated that the interim results are promising when compared to existing treatments. This condition does not have FDA-approved agents, and there exists a fragmented treatment landscape post-frontline therapy, factors that suggest the notable market opportunity for NXC-201 and support the buy rating for Immix Biopharma, Inc. (NASDAQ:IMMX). Immix Biopharma, Inc. (NASDAQ:IMMX) is a biopharmaceutical company that develops therapies for inflammatory diseases and cancer. While we acknowledge the potential of IMMX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
5 hours ago
- Yahoo
Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target
In a report released on June 4, Dennis Ding from Jefferies maintained a Buy rating on Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) with a price target of $80.00. The analyst based the rating on the company's strategic developments and promising pipeline. One of the primary reasons behind the rating was the anticipated Phase II data for the oral treatment for hypothalamic obesity (HO). It is expected to deliver notable BMI reduction and has been de-risked, thereby extending the potential of the franchise beyond the current expiration dates. A scientist conducting research in a laboratory, studying a Petri dish with advanced biopharmaceuticals. The analyst stated that management is confident in the weekly subcutaneous (subQ) treatment, which closely aligns with the previously approved setmelanotide, and thus further adds to the positive outlook for Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM). According to Ding, the setmelanotide Phase II open-label trial for Prader-Willi Syndrome can also pave the way for a significant opportunity if successful, even after its previous challenges. Management is focusing on patient starts instead of the immediate revenue post-launch, and this strategy supports the long-term growth prospects, according to the analyst. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a commercial-stage biopharmaceutical company that develops and commercializes therapeutics for the treatment of rare diseases. Its product pipeline includes IMCIVREE (setmelanotide), a precision medicine that treats hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. The company also has other programs, including a preclinical suite of investigational candidates to treat congenital hyperinsulinism and a clinical development program for setmelanotide in other rare MC4R pathway diseases. While we acknowledge the potential of RYTM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.
